A Pilot Study Evaluating Efficacy of a Topical Klotho Anti-Aging Serum to Treatable Visible Photoaging

Up to 90% of skin aging is caused by ultraviolet radiation, resulting in significant photodamage and clinical burden. Klotho Skin Serum, formulated with the Klotho protein for anti-aging, shows promise based on preclinical studies exploring its physiological functions and therapeutic applications.

To investigate the efficacy and safety of Klotho Skin Serum in improving visible signs of photoaging.

Female participants (N=16) aged 30 to 60 years with mild to moderate photodamage received Klotho Skin Serum twice daily for 12 weeks. The primary efficacy endpoint was the investigator evaluated global improvement in skin aging (fine lines and wrinkles) at Week 12.

Global improvements in skin aging were reported with Klotho Skin Serum throughout the study. At Week 12, statistically significant improvements from baseline were observed with Klotho Skin Serum (p<0.001) with significant improvements also reported at all timepoints. The application of Klotho Skin Serum led to robust improvements in key secondary outcomes from baseline to Week 16, including notable reductions in photodamage, erythema, wrinkles, and dyschromia.

Klotho protein containing serum is an efficacious and safe treatment option to address photodamage and to improve the visible signs of photodamage and skin aging. Large-scale clinical studies are warranted to further evaluate its use in skin aging.